print_label | resize_label

Referral and reimbursement and support with Access 360TM

Coverage and Reimbursement and Support

DESCRIPTION

  • Access 360 has a team of dedicated specialists available to assist in identification of coverage specific to AstraZeneca specialty products
  • Access 360 can offer support to parents and caregivers with the referral process as well as address barriers to
    access, such as prior authorization, denials, and patient out-of-pocket (OOP) costs

Referral Submission

DESCRIPTION

  • Access 360 provides a weekly reconciliation report to all contracted specialty pharmacy providers,
    which includes all patient referrals submitted and date of submission. If parents or caregivers need assistance
    or have questions, please direct them to call 1-844-ASK-A360 or speak with their healthcare provider

Patient Access Programs

DESCRIPTION

  • AstraZeneca is dedicated to helping patients have unencumbered access to necessary AstraZeneca products. Our patient access programs assist patients with high OOP costs
  • AstraZeneca provides complimentary products to eligible patients who are uninsured or rendered uninsured

Billing and Coding Support

DESCRIPTION

  • Access 360 offers coding resources that are designed to provide reimbursement information, important coding
    and billing information, as well as potential codes for prescribers

    These codes may include:

    • ICD-9-CM and ICD-10-CM diagnosis codes
    • National Drug Codes
    • Current Procedural Terminology (CPT) codes
    • Healthcare Common Procedure Coding System for healthcare supplies not identified by CPT codes

For coding or coverage support, please visit www.myaccess360.com
or call 1-844-ASK-A360 to speak with a representative.

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). The recommended dose of Synagis is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of Synagis at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis. Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to Synagis. The relationship between these reactions and the development of antibodies to Synagis is unknown. If a significant hypersensitivity reaction occurs with Synagis, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of Synagis. As with any intramuscular injection, Synagis should be given with caution to children with thrombocytopenia or any coagulation disorder. Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see full Prescribing Information for Synagis, including Patient Information.